Cargando…
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
BACKGROUND: Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug–drug interactions, multidrug combinations often exhibit di...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979534/ https://www.ncbi.nlm.nih.gov/pubmed/36864387 http://dx.doi.org/10.1186/s12874-023-01867-y |